Glycoprotein IIb/IIIa

Glycoprotein IIb/IIIa (GP IIb/IIIa), also known as integrin α_IIbβ₃, is a cell membrane glycoprotein complex found on platelets. It is crucial for platelet aggregation, acting as a receptor for fibrinogen, von Willebrand factor, fibronectin, vitronectin, and thrombospondin. These interactions are essential for the blood clotting process, making GP IIb/IIIa a key target for antiplatelet drugs.

Structure and Function

GP IIb/IIIa is a member of the integrin family of adhesion molecules. It is composed of two subunits: α_IIb and β₃. The α_IIb subunit is unique to platelets, whereas the β₃ subunit can also pair with the α_v subunit in other cells to form the integrin α_vβ₃, which is involved in a variety of cell adhesion processes.

Upon platelet activation, GP IIb/IIIa undergoes a conformational change that allows it to bind to its ligands, most notably fibrinogen. This binding is crucial for the cross-linking of platelets, leading to the formation of a platelet plug in the initial phases of clot formation.

Clinical Significance

The critical role of GP IIb/IIIa in platelet aggregation and thrombus formation makes it an important target for therapeutic intervention in conditions where inhibition of platelet function is desirable, such as acute coronary syndrome, percutaneous coronary intervention, and other thrombotic disorders.

Antiplatelet Drugs Targeting GP IIb/IIIa

Several antiplatelet drugs have been developed to inhibit the function of GP IIb/IIIa, thereby preventing platelet aggregation. These include:

• Abciximab: A monoclonal antibody that binds to GP IIb/IIIa, inhibiting its ability to bind fibrinogen.
• Eptifibatide and Tirofiban: Small molecule inhibitors that block the fibrinogen-binding site on GP IIb/IIIa.

These drugs are used in clinical settings to prevent blood clots in high-risk patients, particularly during and after certain types of cardiac procedures.

Genetic and Acquired Disorders

Alterations in the GP IIb/IIIa complex can lead to bleeding disorders, the most notable of which is Glanzmann's Thrombasthenia, a rare genetic condition characterized by a deficiency or dysfunction of GP IIb/IIIa. Patients with this condition have impaired platelet aggregation, leading to increased bleeding tendency.

Research Directions

Research continues to explore the role of GP IIb/IIIa in thrombosis and hemostasis, as well as its potential as a therapeutic target in other diseases. Novel drug delivery systems and targeting strategies are being developed to enhance the efficacy and reduce the side effects of GP IIb/IIIa inhibitors.

See Also

• Platelet
• Blood clot
• Integrin
• Thrombosis
• Hemostasis

‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian